Harpreet Singh was named CEO of Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Whatever comes out of Congress on the “repeal and replace” of the Affordable Care Act (ACA or Obamacare) matters because it will affect the bottom line of the life sciences industry as well as all of its industry partners.
Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company
Clinical-stage biopharmaceutical company Gemphire Therapeutics Inc. and privately held clinical-stage biotechnology company NeuroBo Pharmaceuticals Inc. jointly announced a definitive agreement whereby NeuroBo will merge with a wholly owned subsidiary of Gemphire in an all-stock transaction.
While Boston tends to get the lion’s share of recognition as the premier biopharma hub on the East Coast of the United States, other cities and states are looking to make their names known as a strong location for the industry. New Jersey, New York and New Hampshire have gone to great lengths to distinguish themselves, but so too has smaller Rhode Island.
Cryoport Inc. and EVERSANA announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.
Lyndra Therapeutics and Gilead Sciences entered a partnership collaboration to develop and market ultra-long-acting oral HIV therapies.
Israel’s Pitango Venture Capital is launching a fund that will reach $150 million to invest in health technology.
The IQVIA report finds that in 2018, 27% of drugs launched were for cancer or its symptoms, and 20% were for infectious diseases.
March 2019 was a busy month for biopharma and medical device company initial public offerings.
There has been a heightened interest in longevity research. Some have noted that older billionaires such as Bill Gates, Michael Bloomberg, Richard Branson and others have been investing heavily into biopharma companies focused on aging and aging-related diseases.
March is National Women’s Month, and BioSpace recognized these 10 women as being especially influential in the biopharma industry.